[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649988":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":57,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":82,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Barbara Ann Karmanos Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Duffy-null phenotype positive","EXPERIMENTAL","In phase 2, Patients with a positive Duffy-null blood test plus standard of care chemotherapy with dose adjustment according to an algorithm created in phase 1 of this study.",[13],"Drug: Standard of Care chemotherapy Following an Algorithm",{"label":15,"type":16,"description":17,"interventionNames":18},"Non-Duffy-null","ACTIVE_COMPARATOR","In phase 2, patients with a negative Duffy-null blood test plus standard of care chemotherapy. Delays\u002Fmodifications based on standard CTCAE (Common Terminology Criteria for Adverse Events) grading.",[19],"Drug: Standard of Care chemotherapy following CTCAE criteria",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Standard of Care chemotherapy Following an Algorithm","Standard of care chemotherapy for solid tumor malignancies with dose adjustment according to the algorithm produced in phase 1 for Duffy-null positive patients",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard of Care chemotherapy following CTCAE criteria","Standard of care chemotherapy for solid tumor malignancies with dose modifications and delays according to the standard of care using CTCAE criteria.",[15],[32],{"name":33,"affiliation":5,"role":34},"Vijendra Singh, M.D.","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","313-576-8381","singhv@karmanos.org",[41],{"facility":42,"status":26,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Karmanos Cancer Institute","Detroit","Michigan","48201","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-83.04575,42.33143,{"lat":52,"lon":51},[55],{"name":33,"role":37,"phone":56,"phoneExt":26,"email":39},"3135768381",{"type":34,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Vijendra Singh","Principal Investigator","100649988","phase-1-impact-of-duffy-null-associated-neutropenia-on-chemotherapy-dosing-100649988",false,"NCT07743086","Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing","A Prospective Study of Duffy-null Associated Absolute Neutropenia and Its Impact on Chemotherapy Dosing","Inclusion Criteria:\n\n* Participant must self-identify as being of Middle Eastern or African descent.\n* Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive.\n\n  * Melanoma is allowed; sarcoma is not eligible.\n  * Secondary malignancies are allowed.\n  * Participants who have received only surgery alone as treatment are eligible\n* Participant must be between the ages of 18-80.\n* Participant or their legally authorized representative (LAR) must be able to understand a written informed consent document and be willing to sign it.\n\nExclusion Criteria:\n\n* Participants with active and uncontrolled bacterial, viral, or fungal infection requiring IV antibiotics.\n\n  • Participants may be eligible for the study if the infection is deemed to be under control per investigator's discretion.\n* Participants who have ever received cytotoxic chemotherapy.\n\n  • Those who have already started a chemotherapy regimen with moderate likelihood of developing neutropenia will be considered for enrollment at the principal investigator's discretion.\n* Participants who are receiving concurrent chemo-radiation treatment.\n* Participants who are taking any other investigational drugs.\n* Participants who are pregnant or breastfeeding.\n* Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to follow the treatment plan.","ALL","18 Years","80 Years",{"count":71,"type":72},886,"ESTIMATED","INTERVENTIONAL",[75,76],"PHASE1","PHASE2","The goal of this clinical trial is to:\n\n* In Phase 1 (observational) to develop an algorithm for treatment of Duffy-null positive patients for chemotherapy dosing\n* In Phase 2 (interventional), use the algorithm created in phase 1 to adjust chemotherapy dosing for Duffy-null patients",[79],"Solid Tumor Cancer",[81],"Duffy-null","NOT_YET_RECRUITING","2026-07-29",{"date":85,"type":86},"2026-08-03","ACTUAL",{"date":88,"type":72},"2026-09",{"date":90,"type":72},"2029-04-30",{"name":5,"class":6},1]